Does Proactive Therapy Reduce Relapse in Atopic Dermatitis? A Systematic Review and Meta-Analysis

Authors

  • Thalia Sebastian Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Khairun Najda Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia
  • Kathy Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.71456/jik.v5i1.2529

Keywords:

Atopic Dermatitis, Proactive Therapy, Maintenance Therapy, Relapse, Randomized Controlled Trials

Abstract

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a high relapse rate. Proactive therapy, which involves intermittent application of topical anti-inflammatory agents after clinical remission, was developed to suppress subclinical inflammation and prevent relapse. Objective: This study aimed to evaluate the effectiveness and safety of proactive maintenance therapy compared with reactive therapy in preventing relapse in AD patients. Methods: A systematic review and meta-analysis were conducted following the PRISMA 2020 guidelines. A literature search was conducted on PubMed, CENTRAL, ClinicalTrials.gov, and OpenAlex. Inclusion criteria included RCTs comparing proactive therapy with reactive therapy or emollient control in patients with disease stabilization. Outcomes were analyzed using a random-effects model. Results: Eight RCTs met the inclusion criteria. Meta-analysis showed that proactive therapy was associated with a significant reduction in relapse rates (Odds Ratio = 0.31; 95% CI 0.17–0.58; p<0.001) and a prolongation of time to first relapse (Hazard Ratio = 0.16; 95% CI 0.04–0.60; p=0.007). Individual studies consistently demonstrated prolonged remission with both TCS and TCI. The safety profile demonstrated favorable outcomes with no evidence of skin atrophy with long-term use. Conclusion: Proactive therapy is an effective, evidence-based strategy for long-term AD control, significantly reducing the frequency of relapses without clear evidence of increased serious adverse events during the reported study period

References

Berth-Jones, J., Damstra, R.J., Golsch, S., Livden, J.K., van Hooteghem, O., Allegra, F., & Oostenbrink, A.J. (2003). Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: Randomised, double blind, parallel group study. BMJ, 326(7403), 1367.https://doi.org/10.1136/bmj.326.7403.1367

Breneman, D., Fleischer, A.B., Jr., Abramovits, W., Zeichner, J.A., Goldstein, B., Kirsner, R.S., & Paller, A.S. (2008). Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. Journal of the American Academy of Dermatology, 58(6), 990–999.

Guttman-Yassky, E., Bissonnette, R., Ungar, B., Puig, L., Papp, K., Lain, E., ... & Simpson, E.L. (2019). Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 143(1), 155–172.

Guttman-Yassky, E., Waldman, A., Ahluwalia, J., Ong, PY, Eichenfield, LF, & Atopic Dermatitis Research Network. (2017). Atopic dermatitis: Pathogenesis. Seminars in Cutaneous Medicine and Surgery, 36(3), 100–103.

Langan, S. M., Irvine, A. D., & Weidinger, S. (2020). Atopic dermatitis. The Lancet, 396(10247), 345–360.

Lax, S. J., Harvey, J., Axon, E., Howells, L., Santer, M., Ridd, M. J., Lawton, S., Langan, S. M., & Smith, C. H. (2022). Strategies for using topical corticosteroids in children and adults with eczema. Cochrane Database of Systematic Reviews, 3(3), CD013356.

Liu, L., & Ong, G. (2018). A randomized, open-label study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream in combination with regular emollient skin care in reducing the risk of relapse in pediatric patients with stabilized atopic dermatitis. Journal of Dermatological Treatment, 29(5), 501–509.

Paller, AS, Eichenfield, LF, Kirsner, RS, et al. (2008). Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: A new paradigm for use. Pediatrics, 122(6), e1210–e1218.

Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I., Hoffmann, TC, Mulrow, CD, Shamseer, L., Tetzlaff, JM, Akl, EA, Brennan, SE, Chou, R., Glanville, J., Grimshaw, JM, Hróbjartsson, A., Lalu, MM, Li, T., Loder, E.W., Mayo-Wilson, E., McDonald, S., ... Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71.https://doi.org/10.1136/bmj.n71

Peserico, A., Städtler, G., Sebastian, M., Fernandez, R.S., Kapp, A., & Schuppe, H.C. (2008). Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: A multicentre, randomized, double-blind, controlled study. British Journal of Dermatology, 158(4), 801–807.

Schmitt, J., von Kobyletzki, L., Svensson, A., & Apfelbacher, C. (2011). Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: Systematic review and meta-analysis of randomized controlled trials. British Journal of Dermatology, 164(2), 415–428.

Silverberg, J. I. (2017). Public health burden of atopic dermatitis. Dermatologic Clinics, 35(3), 283–289.

Suárez-Fariñas, M., Tintle, S.J., Shemer, A., Chiricozzi, A., Nograles, K.E., Cardinale, I., Fuentes-Duculan, J., Novitskaya, I., Guttman-Yassky, E., & Krueger, J.G. (2011). Non-lesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. Journal of Allergy and Clinical Immunology, 127(4), 954–964.e1–e5.

Thaci, D., Chambers, C., Sidhu, M., & et al. (2010). Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: Clinical efficacy and economic impact over 12 months. Journal of the European Academy of Dermatology and Venereology, 24(9), 1040–1046.

Thaci, D., Reitamo, S., Gonzalez Ensenat, M.A., et al. (2008). Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: Results of a randomized, multicentre, comparative study. British Journal of Dermatology, 159(6), 1348–1356.

Wollenberg, A., Barbarot, S., Bieber, T., Christen-Zaech, S., De Raeve, L., Deleuran, M., Fink-Wagner, A., Gelmetti, C., Gieler, U., Gutermuth, J., Heratizadeh, A., Hijnen, DJ, von Kobyletzki, L.B., Kunz, B., Muraro, A., Schaarschmidt, M.L., Schmid-Grendelmeier, P., Seidenari, S., Simon, D., ... Cork, M.J. (2018). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I. Journal of the European Academy of Dermatology and Venereology, 32(5), 657–682.

Wollenberg, A., & Bieber, T. (2009). Proactive therapy of atopic dermatitis: A review. Current Opinion in Allergy and Clinical Immunology, 9(5), 415–419.

Wollenberg, A., Reitamo, S., Girolomoni, G., Lahfa, M., Ruzicka, T., Healy, E., Giannetti, A., & Bieber, T. (2008). Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy, 63(6), 742–750.

Downloads

Published

2026-11-14

How to Cite

Sebastian, T., Najda, K., & Kathy. (2026). Does Proactive Therapy Reduce Relapse in Atopic Dermatitis? A Systematic Review and Meta-Analysis. JIKES : Jurnal Ilmu Kesehatan, 5(1), 2137–2149. https://doi.org/10.71456/jik.v5i1.2529